Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Acute Myeloid Leukemia Specialty Channel

Acute Myeloid Leukemia
Specialty Channel
News
Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology
Jonathan Canaani, MD
Conference Coverage
Advances in Risk Stratification and Treatment for Patients With AML
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Oncology
Justin Kaner, MD
Conference Coverage
Optimizing Treatment Methods Among Patients With Newly Diagnosed AML
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Oncology
News
Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
News
Determining Optimal Daunorubicin Dosing and 7 + 3 Induction Cycles for Frontline AML Treatment
10/04/2024
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once...
10/04/2024
Oncology
Quiz
Combination Iadademstat and Azacitidine for Patients With Patients With Newly Diagnosed AML
09/25/2024
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to...
09/25/2024
Oncology
News
New Risk Stratification Model Provides Prognostic Data on Survival Post-AlloHCT for Older Patients With AML and High-Risk MDS
09/17/2024
The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...
The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...
The AML60+ classification system...
09/17/2024
Oncology
News
Poor Prognosis for Subset of Patients With AML With Monocytic Differentiation Treated With Frontline Venetoclax and Hypomethylating Agents
08/28/2024
Study data shows that a poor prognosis following treatment of frontline venetoclax and hypomethylating agents was demonstrated among a subset of patients with newly diagnosed acute myeloid leukemia with a monocytic immunophenotype.
Study data shows that a poor prognosis following treatment of frontline venetoclax and hypomethylating agents was demonstrated among a subset of patients with newly diagnosed acute myeloid leukemia with a monocytic immunophenotype.
Study data shows that a poor...
08/28/2024
Oncology
News
MRD Monitoring for Potential for Relapse Following Allogeneic Hematopoietic Cell Transplantation Among Patients With AML
08/28/2024
According to a study, a detection benefit was shown in next-generation sequencing monitoring of measurable residual disease as related to potential for relapse for patients with acute myeloid leukemia after alloHCT, which supports monthly...
According to a study, a detection benefit was shown in next-generation sequencing monitoring of measurable residual disease as related to potential for relapse for patients with acute myeloid leukemia after alloHCT, which supports monthly...
According to a study, a...
08/28/2024
Oncology
News
Complete Remission With Partial Hematological Recovery Shows Benefit as Palliative End Point for Nonmyelosuppressive Treatment of Patients With AML
08/14/2024
Complete remission with partial hematological recovery as an efficacy end point was found to correlate with clinical benefits associated with clinically meaningful palliative effects for the treatment of patients with acute myeloid leukemia...
Complete remission with partial hematological recovery as an efficacy end point was found to correlate with clinical benefits associated with clinically meaningful palliative effects for the treatment of patients with acute myeloid leukemia...
Complete remission with partial...
08/14/2024
Oncology
Curtis Lachowiez, MD
Videos
Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology

Advertisement

News

Curtis Lachowiez, MD
Videos
Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Iomab-B Led Allogeneic Hematopoietic Cell Transplantation vs Standard of Care for Older Patients With R/R AML
06/25/2024
According to data from the 2024 EHA Congress, long-term results of the phase 3 SIERRA trial demonstrated that conditioning and induction with 131I-apamistamab (Iomab-B) was well-tolerated and allowed for access to HCT with curative potential...
According to data from the 2024 EHA Congress, long-term results of the phase 3 SIERRA trial demonstrated that conditioning and induction with 131I-apamistamab (Iomab-B) was well-tolerated and allowed for access to HCT with curative potential...
According to data from the 2024...
06/25/2024
Oncology
News
Olutasidenib Demonstrates Efficacy for Patients With R/R IDH1-Mutated AML Previously Treated With Venetoclax
06/24/2024
Olutasidenib treatment demonstrated efficacy and a consistent safety profile for patients with relapsed/refractory mutant IDH1 acute myeloid leukemia previously treated with venetoclax, according to a subset analysis from a phase 2 study.
Olutasidenib treatment demonstrated efficacy and a consistent safety profile for patients with relapsed/refractory mutant IDH1 acute myeloid leukemia previously treated with venetoclax, according to a subset analysis from a phase 2 study.
Olutasidenib treatment...
06/24/2024
Oncology
News
Reduced-Dose Azacitidine Plus Venetoclax as Maintenance Therapy for Patients With AML Following Intensive or Low-Intensity Induction
06/11/2024

Gina Tomaine

Gina Tomaine
According to a phase 2 trial, low-dose azacitidine plus venetoclax was found to be a feasible maintenance strategy for patients with acute myeloid leukemia following intensive and low-intensity induction.
According to a phase 2 trial, low-dose azacitidine plus venetoclax was found to be a feasible maintenance strategy for patients with acute myeloid leukemia following intensive and low-intensity induction.
According to a phase 2 trial,...
06/11/2024
Oncology
News
Oral Decitabine and Cedazuridine Plus Venetoclax Shows Efficacy, Safety for Older or Unfit Patients With AML
05/31/2024

By Gina Tomaine

By Gina Tomaine
Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.
Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.
Decitabine and cedazuridine plus...
05/31/2024
Oncology
News
Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD
05/03/2024

Amber Denham

Amber Denham
According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...
According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...
According to a recent trial,...
05/03/2024
Oncology
News
Venetoclax With Low-Dose Cytarabine Demonstrates Efficacy, Tolerability for Patients With AML at First MRD or Oligoblastic Relapse
04/18/2024

Amber Denham

Amber Denham
Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.
Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.
Venetoclax with low-dose...
04/18/2024
Oncology
News
Hypomethylating Agents Plus Venetoclax Regimen Post-Allogeneic Hematopoietic Cell Transplant Relapse for Patients With AML
04/02/2024

Jordan Kadish

Jordan Kadish
The combination of hypomethylating agents plus venetoclax post-allogeneic hematopoietic cell transplant relapse demonstrated efficacy among patients with acute myeloid leukemia, with possibly better outcomes among patients with NPM1 and IDH...
The combination of hypomethylating agents plus venetoclax post-allogeneic hematopoietic cell transplant relapse demonstrated efficacy among patients with acute myeloid leukemia, with possibly better outcomes among patients with NPM1 and IDH...
The combination of...
04/02/2024
Oncology
News
Crenolanib Plus Intensive Chemo Demonstrates Efficacy for Patients With Newly Diagnosed FLT3-Mutant AML
04/01/2024

Jordan Kadish

Jordan Kadish
Crenolanib plus intensive chemotherapy demonstrated high rates of deep responses and long-term survival as well as tolerable safety among patients with newly diagnosed FLT3-mutant acute myeloid leukemia.
Crenolanib plus intensive chemotherapy demonstrated high rates of deep responses and long-term survival as well as tolerable safety among patients with newly diagnosed FLT3-mutant acute myeloid leukemia.
Crenolanib plus intensive...
04/01/2024
Oncology

Interactive Features

Quiz
Treating Acute Myeloid Leukemia With Aspacytarabine
03/05/2024
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine...
03/05/2024
Oncology
Quiz
Fractionated Vs Single-Dose Gemtuzumab Ozogamicin Among Older Patients With AML
02/15/2024
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated...
02/15/2024
Oncology
Quiz
Humanized Bispecific Antibody Vibecotamab for R/R AML
02/07/2024
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering...
02/07/2024
Oncology
Quiz
Treating TP53-Mutated AML With Venetoclax Plus HMA Therapy
01/10/2024
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to...
01/10/2024
Oncology
Quiz
Fludarabine-Based Regimen Vs Standard 7 + 3 Regimen for WT1-Mutated AML
12/09/2023
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did...
12/09/2023
Oncology
Quiz
Sorafenib Maintenence After AlloHSCT For FLT3-ITD-Mutated AML
12/04/2023
True or False: Results from a post-hoc analysis from a phase 3 trial indicated that sorafenib maintenance after allogeneic hematopoietic stem-cell transplantation (alloHSCT) was effective among patients with FLT3 internal tandem duplication...
True or False: Results from a post-hoc analysis from a phase 3 trial indicated that sorafenib maintenance after allogeneic hematopoietic stem-cell transplantation (alloHSCT) was effective among patients with FLT3 internal tandem duplication...
True or False: Results from a...
12/04/2023
Oncology
Quiz
Azacitidine, Venetoclax, and Pevonedistat Combination for Secondary AML, MDS, or CMML
11/09/2023
True or False: The triplet combination of azacitidine, venetoclax, and pevonedistat yielded encouraging responses among patients with newly diagnosed secondary AML, MDS, or CMML.
True or False: The triplet combination of azacitidine, venetoclax, and pevonedistat yielded encouraging responses among patients with newly diagnosed secondary AML, MDS, or CMML.
True or False: The triplet...
11/09/2023
Oncology
Quiz
Treating AML With Gemtuzumab Ozogamicin Plus Intensive Chemotherapy
09/26/2023
True or False: Findings from a phase 3 trial indicate that the addition of anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin to intensive chemotherapy demonstrated promising efficacy among patients with newly diagnosed NPM1-mutated AML.
True or False: Findings from a phase 3 trial indicate that the addition of anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin to intensive chemotherapy demonstrated promising efficacy among patients with newly diagnosed NPM1-mutated AML.
True or False: Findings from a...
09/26/2023
Oncology
Quiz
Treating R/R AML With Venetoclax, Azacitidine, and Homoharringtonine
09/11/2023
According to a phase 2 trial, the combination of venetoclax, azacitidine, and homoharringtonine demonstrated _____ among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, the combination of venetoclax, azacitidine, and homoharringtonine demonstrated _____ among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial,...
09/11/2023
Oncology
Quiz
Quizartinib for Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3/ITD Mutations
08/03/2023
True or False: The FDA approved quizartinib with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for patients with newly diagnosed acute...
True or False: The FDA approved quizartinib with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for patients with newly diagnosed acute...
True or False: The FDA approved...
08/03/2023
Oncology

Advertisement

Advertisement

Advertisement

Recent Stories

News
Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology
Jonathan Canaani, MD
Conference Coverage
Advances in Risk Stratification and Treatment for Patients With AML
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Oncology
Justin Kaner, MD
Conference Coverage
Optimizing Treatment Methods Among Patients With Newly Diagnosed AML
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Oncology
News
Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
News
Determining Optimal Daunorubicin Dosing and 7 + 3 Induction Cycles for Frontline AML Treatment
10/04/2024
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once...
10/04/2024
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement